8-K: Upstream Bio's Verekitug Shines in Severe Asthma Trial

Upstream Bio announced positive top-line results from its Phase 2 VALIANT trial for verekitug in severe asthma, meeting its primary endpoint with significant reductions in exacerbation rates.

Summary

• Upstream Bio reported positive top-line results from the Phase 2 VALIANT clinical trial evaluating verekitug for severe asthma.
• The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER).
• Verekitug 100 mg dosed every 12 weeks (q12w) reduced AAER by 56% (p<0.0003) compared to placebo.
• Verekitug 400 mg dosed every 24 weeks (q24w) reduced AAER by 39% (p<0.02) compared to placebo.
• Clinically meaningful improvements in lung function, measured by forced expiratory volume in one second (FEV1), were observed: 122 mL at week 60 with 100 mg q12w and 139 mL at week 60 with 400 mg q24w.
• Verekitug suppressed exhaled nitric oxide (FeNO) compared to placebo by 20.4 ppb (p<0.0003) with 100 mg q12w and by 26.3 ppb (p<0.0001) with 400 mg q24w at week 60.
• These FeNO data represented a mean 43.5% (p=0.03) reduction from baseline in the 100 mg q12w group and a mean 44.9% (p=0.03) reduction from baseline in the 400 mg q24w group.
• Verekitug was generally well tolerated across all active doses, exhibiting a favorable safety profile consistent with previous studies.
• Over 90% of eligible patients from the VALIANT trial have rolled over to the Phase 2 VALOUR long-term extension study.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive announcement, demonstrating strong clinical efficacy and a favorable safety profile for verekitug, which significantly de-risks the asset and paves the way for Phase 3 development.

Positives

• Statistically significant and clinically meaningful reduction in annualized asthma exacerbation rate (AAER) with both 100 mg q12w (56% reduction, p<0.0003) and 400 mg q24w (39% reduction, p<0.02) dosing.
• Clinically meaningful improvements in lung function (FEV1) of 122 mL (100 mg q12w) and 139 mL (400 mg q24w) at week 60.
• Significant suppression of exhaled nitric oxide (FeNO) by 20.4 ppb (100 mg q12w, p<0.0003) and 26.3 ppb (400 mg q24w, p<0.0001) at week 60.
• Favorable safety profile, generally well tolerated across all active doses, consistent with previous studies.
• High patient retention rate with over 90% of eligible patients rolling over to the VALOUR long-term extension study.
• Verekitug is the only known clinical-stage antagonist targeting the TSLP receptor, offering a differentiated product profile.
• Positive results from the VIBRANT trial in CRSwNP were also mentioned, indicating broader potential for verekitug.

Negatives

• A third low-dose treatment group (100 mg q24w) demonstrated a statistically significant effect on AAER but did not provide consistent improvements in other endpoints.
• Secondary endpoints (changes in air exhalation, nitric oxide exhalation, patient-reported asthma control) were not designed with sufficient power to detect statistically significant effects, though some pre-specified analyses at week 24 did show significance for FEV1 and FeNO.

Risks

• Ability to advance verekitug through clinical development and obtain regulatory approval on expected timelines, if at all.
• Initiation, timing, progress, and results of clinical trials.
• Ability to fund development activities and achieve development goals.
• Dependence on third parties to conduct clinical trials, manufacture, and commercialize verekitug.
• Ability to attract, hire, and retain key personnel, and protect intellectual property.
• Financial condition and need for substantial additional funds to complete development and commercialization.
• Regulatory developments and approval processes of the U.S. FDA and comparable foreign authorities.
• Competition and industry factors.
• Actual results, levels of activity, safety, efficacy, performance, or events and circumstances could differ materially from forward-looking statements.

Future Outlook

Upstream Bio intends to rapidly advance verekitug into Phase 3 trials for severe asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) following planned regulatory interactions. The company also continues to progress verekitug in its ongoing Phase 2 VENTURE trial for Chronic Obstructive Pulmonary Disease (COPD), with over 60% patient enrollment to date. The VALIANT trial endpoints were designed to potentially produce data that could support submissions for product approval.

Management Comments

• "We are excited to share these robust data from VALIANT, which indicate the potential of verekitugs meaningful clinical effect in severe asthma and provide a strong foundation as we advance verekitug into Phase 3 clinical trials as quickly as possible." Aaron Deykin, MD, Chief Medical Officer and Head of Research & Development at Upstream Bio.
• "These compelling findings from VALIANT strengthen verekitugs potential to advance the standard of care with a highly competitive efficacy profile and less frequent dosingan important combination for people living with severe asthma." Rand Sutherland, MD, Chief Executive Officer of Upstream Bio.
• "We intend to rapidly advance verekitug into Phase 3 trials in severe asthma and CRSwNP. In parallel, we also continue to progress verekitug in our ongoing Phase 2 VENTURE trial in patients with COPD, where we have enrolled more than 60% of patients to date." Rand Sutherland, MD, Chief Executive Officer of Upstream Bio.
• "As we transition into a late clinical-stage company pursuing substantial market opportunities, our focus remains on disciplined execution and expanding Upstream Bios capabilities to support long-term growth." Rand Sutherland, MD, Chief Executive Officer of Upstream Bio.
• "These data suggest that verekitug can potentially offer patients meaningful improvements in their breathing and asthma symptoms with less frequent dosing than the currently available biologics, and I believe that verekitug could represent an important advancement for individuals living with severe asthma." Michael Wechsler, MD, MMSc, Professor of Medicine, Director of National Jewish Cohen Family Asthma Institute.

Industry Context

StockSavvy.ai notes that severe asthma affects approximately 350 million people worldwide, with 5-10% suffering from severe asthma, representing a significant unmet medical need. The market for biologic-eligible severe asthma patients in the US is estimated at 1.3 million, but current biologic use is limited. Verekitug, as the only known clinical-stage antagonist targeting the TSLP receptor, positions Upstream Bio uniquely in a competitive landscape, potentially offering a differentiated efficacy profile and less frequent dosing compared to existing biologics. The positive results in severe asthma, coupled with prior positive results in CRSwNP, suggest broad applicability for TSLP receptor inhibition in inflammatory diseases.

Comparison to Industry Standards

• Verekitug's potential for less frequent dosing (q12w and q24w) is a key differentiator compared to currently available biologics for severe asthma, which often require more frequent administration.
• The 56% reduction in AAER with 100 mg q12w and 39% reduction with 400 mg q24w are competitive efficacy metrics within the severe asthma biologic market. For example, Tezepelumab (AstraZeneca/Amgen), another TSLP inhibitor, showed a 56% reduction in AAER in its NAVIGATOR trial for the overall population, and 79% in patients with high baseline eosinophil counts. Dupilumab (Sanofi/Regeneron), an IL-4/IL-13 inhibitor, showed a 47.7% reduction in AAER in its LIBERTY ASTHMA QUEST trial. Verekitug's results appear to be in a similar range of efficacy for AAER reduction, with the added benefit of potentially less frequent dosing.
• Improvements in FEV1 (122 mL and 139 mL) and FeNO suppression are also important clinical outcomes that compare favorably with other approved biologics.

Stakeholder Impact

• Shareholders: Positive impact due to successful clinical trial results, de-risking of the lead asset, and progression towards Phase 3, potentially increasing company valuation and future revenue prospects.
• Patients (Severe Asthma): Potential for a new, effective treatment option with less frequent dosing, leading to improved quality of life, reduced exacerbations, and better lung function.
• Healthcare Providers: Verekitug could offer a valuable new tool in managing severe asthma, especially given its differentiated mechanism and dosing schedule.
• Employees: Positive impact on morale and job security due to successful clinical development and company growth.
• Regulatory Authorities: Will engage in discussions regarding Phase 3 trial design and potential product approval submissions.

Next Steps

• Advance verekitug into Phase 3 trials in severe asthma.
• Advance verekitug into Phase 3 trials in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
• Engage in planned regulatory interactions to guide dose selection and trial design for Phase 3.
• Continue the ongoing Phase 2 VENTURE trial in patients with COPD.
• Present additional details from the VALIANT trial at a future medical conference.
• Management to host a live webcast on February 11, 2026, at 8:00 a.m. ET.

Key Dates

Recommendation

The positive top-line results from the Phase 2 VALIANT trial for verekitug in severe asthma are highly encouraging, demonstrating statistically significant and clinically meaningful reductions in asthma exacerbation rates and improvements in lung function and FeNO, coupled with a favorable safety profile. The high patient rollover rate to the long-term extension study further underscores confidence in the drug. These results significantly de-risk the asset and provide a strong foundation for advancing into Phase 3 trials, positioning Upstream Bio for substantial market opportunities in severe respiratory disorders. The differentiated mechanism of action and potential for less frequent dosing could make verekitug a highly competitive product in a large and underserved market.

Keywords

Upstream Bio, UPB, Verekitug, Severe Asthma, Phase 2 VALIANT, Clinical Trial, TSLP receptor, Asthma Exacerbation Rate, FEV1, FeNO, Biotechnology, Inflammatory Diseases, Respiratory Disorders, CRSwNP, COPD